Abstract P5-21-28: Phase Ib study of ribociclib + letrozole in Asian non-Japanese patients with hormone receptor-positive, HER2-negative advanced breast cancer: MONALEESASIA

Autor: J Chiu, Y Han, Yoon Sim Yap, C Germa, J Suarez-Vizcarra, Yoshinori Ito, X Liu

Publikováno v: Cancer Research. 78:P5-21

Background: First-line ribociclib (RIB; a selective cyclin-dependent kinase 4/6 inhibitor) + letrozole (LET) significantly prolonged progression-free survival vs placebo + LET in patients (pts) with hormone receptor-positive (HR+), human epidermal gr

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::36b94dce56ae992da1042e705e1dad6c
https://doi.org/10.1158/1538-7445.sabcs17-p5-21-28

Abstract P1-14-05: Ribociclib dose recommendations for potential pharmacokinetic drug interaction and in special patient populations with organ impairment

Autor: Marc Laisney, Shu Yang, Tanay S. Samant, Martin Mueller-Zsigmondy, Mohamed Elmeliegy, Ahmed M. Abdelhady, Abhijit Chakraborty, Michelle Quinlan, K-I. Umehara, Yen-Shen Lu, X Liu, Felix Huth, C. Germa

Publikováno v: Cancer Research. 78:P1-14

Background: Ribociclib (Kisqali®) is a CDK4/6 inhibitor, recently approved in the U.S. as a first line therapy for HR+/HER2- advanced breast cancer (ABC) in combination with an aromatase inhibitor. The recommended starting dose is 600 mg/day orally

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::cd9b1be09aa2993dd96d6bb5f9873bfd
https://doi.org/10.1158/1538-7445.sabcs17-p1-14-05

Ribociclib plus letrozole versus letrozole alone in patients with de novo HR+, HER2− advanced breast cancer in the randomized MONALEESA-2 trial

Autor: Lowell L. Hart, Cristian Villanueva, Deborah Lindquist, Erik Jakobsen, Carlos L. Arteaga, Joseph T. Beck, Farida Souami, Gabriel N. Hortobagyi, Katarína Petráková, Pierfranco Conte, Joyce O'Shaughnessy, C. Germa, David Cameron, Gabe S. Sonke, S. Mondal

Publikováno v: O’shaughnessy, J, Petrakova, K, Sonke, G S, Conte, P, Arteaga, C L, Cameron, D A, Hart, L L, Villanueva, C, Jakobsen, E, Beck, J T, Lindquist, D, Souami, F, Mondal, S, Germa, C & Hortobagyi, G N 2017, ' Ribociclib plus letrozole versus letrozole alone in patients with de novo HR+, HER2− advanced breast cancer in the randomized MONALEESA-2 trial ', Breast cancer research and treatment . https://doi.org/10.1007/s10549-017-4518-8
Breast Cancer Research and Treatment

Purpose Determine the efficacy and safety of first-line ribociclib plus letrozole in patients with de novo advanced breast cancer. Methods Postmenopausal women with HR+ , HER2− advanced breast cancer and no prior systemic therapy for advanced disea

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::49235fc434d9b04769919f70390e2b93
https://doi.org/10.1007/s10549-017-4518-8

Discovery and development of novel therapies in advanced breast cancer: rapid development of ribociclib

Autor: B. Hewes, G. Caponigro, S.J. Scherer, Samit Hirawat, C. Germa, Pabak Mukhopadhyay, M. Miller

Publikováno v: Annals of Oncology

The treatment landscape for advanced breast cancer has changed radically over the last 30–40 years with the refinement of surgical and radiographic techniques, approval of a range of chemotherapy regimens in the adjuvant and metastatic settings, an

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b5ada953fc0144e5b6e2cf20bbd18600
https://doi.org/10.1093/annonc/mdx226

Abstract P4-22-18: Phase Ib safety, efficacy, and molecular analysis of ribociclib (LEE011) plus letrozole for the treatment of ER+, HER2– advanced breast cancer

Autor: Dejan Juric, S-A. Im, Roohi Ismail-Khan, Andrew M Wardley, Samit Hirawat, Yingbo Wang, R H de Boer, IA Mayer, Laura García-Estévez, Pamela N. Munster, C. Germa, L Teixeira, Faye Su, Carlos Becerra, Erika Hamilton

Publikováno v: Cancer Research. 77:P4-22

Background: Aromatase inhibitors are the standard first-line treatment for patients (pts) with estrogen receptor-positive (ER+), human epidermal growth factor receptor 2-negative (HER2–) advanced breast cancer (aBC). However, resistance via disrupt

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::d24d63d85636112d5489266d6cae8d93
https://doi.org/10.1158/1538-7445.sabcs16-p4-22-18